Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 42

  • 960 clinical trials
  • 390 recruiting
  • 346 conditions
  • 28 countries

Conditions in this area

346 conditions with trials, the busiest first

Breast cancer170Prostate cancer102Ovarian cancer90Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer42Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer19Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+322

Clinical trials in Reproductive system and breast disorders

960 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

960 clinical trials

Breast cancer+1

Not yet recruiting

Study of Azithromycin, Doxycycline, and Sodium Ascorbate for Patients with Early-Stage Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Doxycycline Hyclate
  • Sponsor:Azienda Ospedaliero Universitaria Pisana

Breast cancer female

Not yet recruiting

Study of Atezolizumab, Pertuzumab, and Trastuzumab for Patients with HER2 Positive Early High-Risk and Locally Advanced Breast Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fondazione Michelangelo

Endometrial cancer

Not yet recruiting

Study Comparing Chemotherapy Alone to Dostarlimab, Paclitaxel, and Carboplatin for Patients with Advanced or Metastatic Endometrial Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Carboplatin
  • Sponsor:Arcagy Gineco

Prostate cancer

Not yet recruiting

Study on Metastatic Prostate Cancer: Evaluating [18F]FAPI-74 and Piflufolastat (18F) for Patients with Advanced Disease

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Piflufolastat (18F)
  • Sponsor:Turku University Hospital

Hormone receptor positive HER2 negative breast cancer

Not yet recruiting

Study on the Effectiveness of Abemaciclib, Inavolisib, and Giredestrant in Patients with Early HR-positive/HER2-negative Breast Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Medica Scientia Innovation Research S.L.

Prostate cancer

Not yet recruiting

Study on Teverelix for Patients with Advanced Prostate Cancer

InvestigationalNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Teverelix
  • Sponsor:Antev Limited

Breast cancer

Not yet recruiting

Study on the Effectiveness of Trastuzumab, Pertuzumab, and Docetaxel for Patients with Early HER2-Positive Breast Cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:HUS-Yhtymae

Infertility female

Not yet recruiting

Study of testosterone gel treatment for women with low ovarian reserve and androgen receptor polymorphism undergoing fertility treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Follitropin Alfa
  • Sponsor:Instituto Bernabeu S.L.

Cervix carcinoma+2

Not yet recruiting

Study on the Effectiveness of Carboplatin and Paclitaxel in Treating Cervical Cancer with Para-aortic Lymph Node Involvement

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Endometrial cancer+3

Not yet recruiting

Study of Disitamab Vedotin for Adults with Previously Treated HER2-Positive Solid Tumors, Including Lung, Head and Neck, Ovarian, and Endometrial Cancers

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Disitamab Vedotin
  • Sponsor:Seagen Inc.

Gastric cancer+2

Not yet recruiting

Study of Disitamab Vedotin and Tucatinib for Patients with Advanced Breast Cancer or Gastric Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Disitamab Vedotin
  • Sponsor:Seagen Inc.

Hormone receptor positive breast cancer

Not yet recruiting

Study Comparing 18F-FDG and 68Ga-FAPI-46 for PET Scans in Patients with Hormone-Positive Breast Cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Academisch Ziekenhuis Maastricht

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab76 clinical trialsLetrozole74 clinical trialsFulvestrant59 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane47 clinical trialsAnastrozole45 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.